Outlook Therapeutics, Inc.

NasdaqCM:OTLK Stock Report

Market Cap: US$59.0m

Outlook Therapeutics Past Earnings Performance

Past criteria checks 0/6

Outlook Therapeutics's earnings have been declining at an average annual rate of -17.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 94.2% per year.

Key information

-17.1%

Earnings growth rate

44.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-94.2%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06
Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

Outlook Therapeutics: A One-Buck Lottery Ticket

Jun 09

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Apr 01
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Revenue & Expenses Breakdown

How Outlook Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:OTLK Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-75300
30 Jun 240-94270
31 Mar 240-159268
31 Dec 230-51270
30 Sep 230-59270
30 Jun 230-6024-31
31 Mar 230-5723-10
31 Dec 220-70230
30 Sep 220-66210
30 Jun 220-651931
31 Mar 220-601620
31 Dec 210-53140
30 Sep 210-53130
30 Jun 210-50120
31 Mar 210-40120
31 Dec 200-45100
30 Sep 200-49100
30 Jun 206-49100
31 Mar 206-5190
31 Dec 197-4590
30 Sep 198-3690
30 Jun 193-38130
31 Mar 193-43130
31 Dec 183-40140
30 Sep 183-48140
30 Jun 185-43120
31 Mar 185-39130
31 Dec 174-39150
30 Sep 174-40160
30 Jun 171-43190
31 Mar 172-68260
31 Dec 162-64220
30 Sep 163-63220
30 Jun 163-71200
31 Mar 164-53120
31 Dec 153-64160
30 Sep 155-53130
30 Sep 149-2170

Quality Earnings: OTLK is currently unprofitable.

Growing Profit Margin: OTLK is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OTLK is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.

Accelerating Growth: Unable to compare OTLK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OTLK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).


Return on Equity

High ROE: OTLK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 13:18
End of Day Share Price 2025/01/13 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Outlook Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets